Trial Information
Phase II Study With Rituximab and CHOP in Patients With Gastric Diffuse Large B-Cell Non-Hodgkin`s Lymphoma
see above
Inclusion Criteria:
- Age > 18 years
- Histologically confirmed primary gastric CD20+ DLBCL
- Written informed consent
- ECOG 0-2
Exclusion Criteria:
- Secondary aggressive Non-Hodgkin`s lymphoma involving the gastric area
- HIV positive patients
- Severe organ dysfunction
- Life expectancy of less than 3 months
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Complete remission rate
Outcome Time Frame:
at end of chemo-immunotherapy
Safety Issue:
No
Principal Investigator
Wolfram Brugger, M.D.
Investigator Role:
Principal Investigator
Investigator Affiliation:
Schwarzwald-Baar Clinic, Academic Teaching Hospital, University of Freiburg
Authority:
Germany: Federal Institute for Drugs and Medical Devices
Study ID:
64-03
NCT ID:
NCT00204659
Start Date:
March 2003
Completion Date:
September 2008
Related Keywords:
- Primary Gastric Diffuse-Large B-Cell Lymphoma
- Rituximab
- CHOP
- DLBCL
- gastric lymphoma
- Lymphoma
- Lymphoma, Non-Hodgkin
- Lymphoma, B-Cell
- Lymphoma, Large B-Cell, Diffuse